Scancell Share Discussion Threads

[gazza] 01/4/2019 10:17

MY head? lol

[inanaco] 01/4/2019 09:31

Gazza
LOL

at least your head is in the cloud

ATB

[gazza] 01/4/2019 07:35

I'm confused now. Prof Durrant didn't say we wouldn't be the next Microsoft, but, she didn't say we would either. How do I know which of the two options is correct?

[inanaco] 31/3/2019 22:44

Bermuda ...

I am happy with a 50% response rate leading to a (CR) my Target
leave you arguing against it

ATB

[bermudashorts] 31/3/2019 21:26

Inanaco,

Serioulsy?

You're trying to justify your comments by the fact that LD didn't actually state that the tumour regression stops?

The target for Modi1 is ABSOLUTELY NOT a 50% complete response rate and no matter how you want to wrap it up, it was incorrect for you to make that claim.

[inanaco] 31/3/2019 14:01

Bermuda the problem with your posts is simple !!

""""It's about you saying that the target for Modi1 in humans is a 50% complete response rate.""""

when did a "target" become fact

what i have tried to get over Moditope works or it does not ..

because if it works it "eradicates" of which regression is part of that ...

now what Lindy did not say is "we expect regression to stop" ATB

[bermudashorts] 31/3/2019 12:11

Spurs,

I wouldn't dream of trying to encourage you to invest and genuinely don't care whether you do or not.

I'm more than happy to discuss the many risks and concerns here but they don't centre around the science, the IP, preclinical or clinical results to date. So bash away if you like but at least do a bit of research first.

[bermudashorts] 31/3/2019 11:37

Spurs,

Yep, no need here to employ consultants to drill down and cut the data every which way in an attempt to suggest benefit - just clear facts.

[gazza] 31/3/2019 11:14

Old, spot on. The irony is, you can take some fairly conservative estimates, factor in dilution and still arrive at rather tasty valuations. These all depend on trials starting and being successful of course.

[gazza] 31/3/2019 11:09

Like I said earlier, you make yourself look incredibly stupid. I hadn't realised you were not done.

[gazza] 31/3/2019 11:07

Spurs, I'm afraid you are mimicking the behaviour of someone you were mocking earlier. You raise one point and when blown out of the water, change it to something completely different.You questioned whether immunotherapy works and when confronted with the facts change it to discussing a small cohort.

[spurs90] 31/3/2019 09:58

And there was me thinking you couldn’t possibly get any reliable data from such a small cohort of patients where have I heard that before???

[ivyspivey] 31/3/2019 09:35

Totally correct Gazza about the way you described Bermuda.
Now if Spurs 90 turned up tomorrow and echoed those same thoughts towards the person who thinks he is the most informed,honest and polite poster but we all know is cut and waste,dishonest and totally obnoxious then we all just think it was an April Fool.

[bermudashorts] 31/3/2019 09:17

Spurs,

Full clinical trial results published below.





From last annual report:-



· Overall, 18 of 20 stage III/IV melanoma patients with resected disease remained alive.

· Of the 16 resected patients who received 2-4 mg doses of SCIB1, only six patients had recurrence of their disease with only two deaths.

· All 14 surviving patients in this group had passed the 5-year time point since study entry. The four patients who had disease recurrence went on to receive other treatments for their melanoma. However, despite having received multiple interventions and recurrences prior to study entry, the other 10 patients had no treatment other than SCIB1

[gazza] 31/3/2019 09:16

Spurs90,
Unfortunately when you turn up on a bulletin board full of investors knowledgeable in both the company and immunotherapy and have a pop at Bermuda - possibly the most informed, honest and polite poster here - you just make yourself look incredibly stupid.

[oldnotwise] 31/3/2019 09:15

EXPECTATIONS...
That has been a problem with the SCLP BBs since 2012.

We ALL agree that the science is promising.
We ALL agree that the commercialisation of SCLP should produce attractive returns for those invested (subject to successful trials).

We DO NOT ALL AGREE that SCLP is a "done deal" for a multi GBP Billions valued company... YET.

FWIW in my view, those who quietly wait and HOPE are more realistic than those who scream "it's in the bag" with associated overegged and frequently unsupportable claims. I say this simply because those who have screamed "it's in the bag" (with attached timelines - so far unfulfilled - ) have to date been shown to have been completely incorrect for virtually all of the last seven years.
Sadly that's indisputable. I wish it wasn't but it is.
So maybe thinking about "Less is More" might be useful to the more excitable "experts" on the Scancell BBs.
However you look at it, the "wait and see" brigade/realists have been shown to have a more sensible view of the investing situation so far.
AIMO
ATB

[gazza] 31/3/2019 09:12

Buywell,Assessing the success of an entire branch of oncology based on the short term share price graph of a single tiny biotech is an interesting proposal.Not sure it will gather much support from the scientific or financial community. But if that is your bag, good luck with it. Hope it enables you to buy well.

[spurs90] 31/3/2019 09:05

Do you have link to confirm data or is it just something you got accustomed to saying ???

[bermudashorts] 31/3/2019 08:47

buywell,

The 18 melanoma patients who are still alive years after vaccination with SCIB1 suggest otherwise.

[spurs90] 31/3/2019 08:34

Rumour is a huge placing on its way here below 5p always amazes me these companies leave it to last minute when they knew they would need to raise this time last year so means they get shafted and we get shafted some more is there anyone other than the local old drunk (Inan)that can give a good reason why to invest here ????

[buywell3] 31/3/2019 08:29

Using immunology to fight cancer does not seem to be working does it according to the chart above in the header

Why is that ?

[bermudashorts] 31/3/2019 07:45

Inanaco,

No we won't see who is correct in a year or so. This discussion isn't about what has been achieved in preclinical research or what either one of us hopes or expects from the Modi1 trial. It's about you saying that the target for Modi1 in humans is a 50% complete response rate. It's not true, it's not correct today and it won't be correct in a year.